If you have been sitting at 0.25 mg or 0.5 mg for months without titration, your dose may simply be too low to produce meaningful results
Medicare beneficiaries who are already receiving coverage from their Part D plan for a GLP-1 for a Medicare-covered use, such as type 2 diabetes, cardiovascular disease risk reduction, or sleep apnea, will continue to access the drug through their Part D plan and not through the Medicare GLP-1 Bridge, which will only provide coverage of GLP-1s when used for obesity
This produces harmful reactive oxygen species (ROS) or free radicals and depletes glutathione
Wu H, Zhang W, Huang M, Lin X, Chiou J
Development of Cagrilintide, a Long-Acting Amylin Analogue
These are usually mild and resolve within days